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Abstract 
Mycoplasma pneumoniae is a common respiratory pathogen, especially in children, responsible for community-acquired pneumo-
nia. Although, in most cases, infections caused by this bacterium follow a benign self-limited clinical course, cases of severe 
respiratory infections have been reported. 
We present two pediatric cases of necrotizing pneumonia due to Mycoplasma pneumoniae. Both patients initially presented with 
low-grade fever, cough and mild respiratory symptoms, however, imaging techniques showed necrotizing pneumonia. Initially, 
a typical bacterial pneumonia was suspected, so antibiotic empiric regimen did not included macrolides. When clinical evolution 
was not adequate, antibiotic treatment was modified in order to provide coverage to unusual pathogens. Both patients finally 
recovered once Mycoplasma was suspected, and oral macrolides were added to their treatment. 
Although M. pneumoniae is a rare cause of necrotizing pneumonia, it must be considered, when usual antibiotic empiric therapy 
is not being successful. Before thinking of uncommon germs, we must remember that: ‘The unusual presentation of a common 
disease is generally more likely than the usual presentation of an uncommon disease’. 
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Introduction
Mycoplasma pneumoniae (M. pneumoniae) 
is a pathogen of the Mycoplasmataceae family, 
characterized by its small size and the absence of 
cell wall, which determines its natural resistance 
to beta-lactam antibiotics [1].
M. pneumoniae is considered a significant 
pathogen of both upper and lower respiratory 
tract infections and it is responsible for more 
than 50% of community-acquired pneumonia 
(CAP) in children over 5 years of age, but a large 
number of microorganisms have been implicated 
as etiologic agents of pneumonia in children [2]. 
Pneumonia caused by M. pneumoniae is referred 
to as “atypical pneumonia”, characterized by 
a benign slow clinical course, low-grade fever, 
malaise and cold-like symptoms. Atypical bacte-
rial pathogens include Chlamydia Trachomatis, 
Chlamydophila Pneumoniae and M. Pneumo-
niae [3]. The initial treatment of children with 
pneumonia is generally empiric, and clinical and 
epidemiologic features can be used to determine 
the most likely pathogens to orientate this therapy 
[4]. In atypical pneumonia, laboratory analyses 
do not generally show substantial alterations, and 
chest radiographs usually have a reticulonodular 
pattern, without clear consolidations. The clinical 
course of pneumonia caused by M. pneumoniae is 
generally good, with very rare complications. Ne-
vertheless, several cases with poor outcomes have 
been previously reported, such as necrotizing 
pneumonia, systemic failure, sepsis, and even 
death, have been attributed to this organism [5]. 
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Figure 1. Chest radiography at diagnosis (Case 1), showing consolida-
tion in the upper lobe of the left lung with an air-fluid level image inside 
the consolidation revealing cavitation and blunting of the costophrenic 
left angle. Pleural effusion and necrotizing pneumonia 
Figure 2. Computed tomography chest scan at diagnosis (Case 1), shows loss of normal pulmonary architecture, decreased parenchymal enhan-
cement and multiple thin-walled cavities extensive lobar consolidation in the left hemithorax with necrosis and pleural effusion
 
We report two pediatric cases with necroti-
zing CAP due to M. pneumoniae, an uncommon 
presentation of a common disease.
Case presentation
Case 1 
Healthy 7-year-old girl, with Down syndro-
me, who presented to the emergency room with 
low-grade fever and cough. Past medical history 
showed only recurrent episodes of obstructive 
bronchitis. On physical examination she was fe-
brile (38.6°C), with a respiratory rate of 32 per mi-
nute (bpm), and normal oxygen saturation (96%), 
with good general condition, and without signs of 
respiratory distress. Chest auscultation identified 
hypoventilation and crackles in the left hemitho-
rax. Chest radiography (Fig. 1) showed consolida-
tion in the upper lobe of the left lung with a small 
air-fluid level image inside the consolidation and 
blunting of the costophrenic angle. Laboratory 
tests, showed moderate increase of acute phase 
reactants: complete blood count (CBC) 16,000 
white cells/mm3, with 91.8% neutrophils; C-re-
active protein (CPR) 22 mg/dL (reference range, 
0–1); and procalcitonin level, 0.5 ng/mL (referen-
ce range, 0–0.5). Patient was admitted to hospital, 
diagnosed as complicated CAP with parapneumo-
nic effusion and necrotizing pneumonia, and pa-
renteral antibiotics were started (cefotaxime 200 
mg/kg/day and clindamycin 40 mg/kg/day). Lung 
ultrasonography confirmed the pleural effusion 
and heterogeneous parenchymal texture, suge-
stive of an underlying necrotizing pneumonia. 
Chest computed tomography (CT) scan (Fig. 2) 
showed extensive lobar consolidation in the left 
hemithorax with necrosis in the left upper lobe, 
left pleural effusion and initial involvement of 
the right upper lobe parenchyma. Repeated ra-
diography showed disease progression, and fever 
and tachypnea persisted. A  thoracentesis was 
performed, and pleural effusion analysis showed: 
cellular count, 120 erythrocytes/mm3; 200 leuco-
cytes/mm3, glucose: 88 mg/dL; protein: 45.4 g/L; 
Isabel San Martin et al., Necrotizing pneumonia by Mycoplasma
307www.journals.viamedica.pl
Figure 3. Computed tomography chest scan at diagnosis (Case 2) demonstrating a necrotic area with thin-walled cavities within the left lower lobe. 
Necrotizing pneumonia, with no evidence of pleural effusion
and lactate dehydrogenase: 211 U/L. After 4 days, 
fever, cough and tachypnea persisted and even 
though general condition was good, patient failed 
to improve as anticipated. Clinical history was 
re-evaluated and further complementary tests 
were done. Although patient had no history of 
previous important infectious diseases, humoral 
and cellular immunity studies were conducted to 
rull out an immunocompromised host, but they 
were both normal. Regarding the etiologic study, 
latex agglutination test of the pleural fluid for 
Streptococcus pneumoniae, and the polymerase 
chain reaction (PCR) analysis of respiratory vi-
ruses were all negative. Blood and pleural fluid 
cultures were also negative. Quantiferon-TB Gold 
Test (QFT) for mycobacteria and Mantoux test 
also were negative. Serology test for M. pneumo-
niae: MP-specific immunoglobulin M (IgM) were 
high, and as a possible atypical pneumonia was 
suspected, oral azithromycin, 10 mg/kg/day for 
5 days, was added, with a  clinical significant 
improvement the day after it was initiated. Acute 
infection was documented by antibody titer chan-
ges (serologic diagnosis increase of MP-specific 
immunoglobulin titer after initial measurement). 
The patient remained hospitalized for 19 days; 
her general condition was good at all times and 
she remained afebrile, once azithromycin was 
started. Consecutive blood tests showed a gradual 
decrease of infectious parameters, and control 
chest x-rays showed reduced consolidation and 
resolution of the pleural effusion after the treat-
ment with macrolide. The patient was followed 
as an outpatient, in the pediatric respiratory 
clinic, and further laboratory tests showed gra-
dual improvement of the infectious-inflammato-
ry parameters, with negative IgM titers and an 
increase of IgG M. pneumonia titers. Chest X-ray 
obtained 2 months after was normal and without 
any sequelae. 
Case 2
Second patient is a previously healthy 3-year-
-old boy, who was brought to the emergency 
room with a history of 6 days of fever, cough and 
myalgia. Oral amoxiciline had not improved the 
symptoms. Physical exam showed good general 
health without respiratory distress. On admission, 
patient was febrile, (38.1°C), pulse rate was 151 
bpm, respiratory rate 32rpm, and oxygen satura-
tion was 98%. Pulmonary auscultation showed 
hypoventilation and crackling, over the left lung 
base. Chest radiography showed left lower lobe 
consolidation with trapped air seen within this 
area. Laboratory test results included a partial in-
crease of acute phase reactants: CBC 22,500 white 
cells/mm3; 77% neutrophils; erythrocyte sedi-
mentation rate, 63 mm/hour; CPR 8.8 mg/dL, and 
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procalcitonin level 0.3 ng/mL. The patient was 
admitted with diagnosis of CAP and intravenous 
antibiotics (cefotaxime 200 mg/kg/day and clin-
damycin 40 mg/kg/day) were administered. His 
respiratory symptoms and respiratory rate did not 
improve, during the first days of treatment, and 
fever persisted. The chest CT scan (Fig. 3) showed 
a necrotizing pneumonia of the left lower lobe, 
with no evidence of pleural effusion. Regarding 
the etiologic agent, no S. pneumoniae antigen was 
found in urine sample, and TBC test and blood 
cultures were all negative. Humoral and cellular 
immunity studies were performed with normal 
results. Viral PCR were negative. Positive serology 
titters of M. pneumoniae were found, suggestive 
of an acute infection (MP-specific-IgM increased 
antibody titers). Oral azithromycin was added 
to the previous treatment and administered for 
5 days. Fever disappeared, patient was eupneic 
and blood analyses showed gradual improvement 
of the infectious-inflammatory parameters. Chest 
X-ray showed gradual decrease in lesion size. 
Chest CT scan showed a decrease in the consoli-
dation size, but several images of air-liquid levels 
persisted, the largest of which was 4.7 cm in dia-
meter at discharge. The boy was followed, as an 
outpatient, in the pediatric respiratory clinic. His 
follow-up radiograph and CT scan were normal 
3 months after and he was negative for IgM and 
had decreased IgG M.pneumonia titers.
Discussion
Community-acquired pneumonia (CAP) is 
defined as an acute infection of the pulmonary 
parenchyma acquired in the community, as di-
stinguished from hospital-acquired pneumonia. 
Childhood CAP is still an important cause of mor-
bidity in the developed world [6]. A large number 
of different microorganisms have been implicated 
as etiologic agents of pneumonia in children, and 
the true prevalence of the etiologic agents in CAP 
is uncertain [7]. Generally in children, clinical 
finding, radiological features and commonly used 
laboratory tests can only provide indirect eviden-
ce of etiology. Necrotizing pneumonia is generally 
caused by gram-positive cocci (Staphylococcus 
aureus, Streptococcus pyogenes, or S. pneumo-
niae) or by anaerobic bacteria, such as Klebsiella 
pneumoniae, more frequently seen in children 
with risk factors for aspiration [8]. 
Complicated CAP requires a broader spec-
trum of antibiotic including beta-lactam-resistant 
and methicillin resistant staphylococcus aureus 
(MRSA) as well as other anaerobes and gram-
negative organisms. Clinical response to empiric 
therapy and results of microbiologic and labo-
ratory studies, will help to determine whether 
changes in antibiotics regimen are needed [9, 10]. 
In our patients, when diagnosis of necrotizing 
pneumonia was made, the empiric antibiotic 
therapy used for typical bacteria was indicated, 
to cover bacterial spectrum generally respon-
sible for this entity, including cefotaxime, and 
clindamycin. When clinical symptoms persisted 
other possibilities were considered such as an 
underlying immunodeficiency condition, the 
development of complications, TB infection or an 
ineffective antibiotic coverage (travels or contact 
with birds or other animals were investigated and 
excluded). The immunodeficiency screening in 
both patients, including a complete blood count, 
cellular and humoral immunity evaluation and 
HIV testing, was normal. The use of a bronchosco-
py, or other more invasive methods, in order to 
obtain a microbiologic diagnosis was evaluated 
but finally not necessary. When positive results 
of M. pneumoniae titers were obtained, and 
atypical pneumonia was clinically suspected, 
azithromycin was added to the treatment, with 
excellent results. 
To assume that M. pneumoniae was the 
etiologic agent in the current cases was compli-
cated; it is impossible to visualize the bacterium 
on Gram staining, and isolating the organism in 
culture is difficult and inefficient. Initially we 
could only rely on a single high antibody titer, 
and a single serologic test has limited values for 
diagnosis, but the subsequent seroconversion 
and the clinical response to macrolides treatment 
supported our findings [9]. 
The polymerase chain reaction (PCR) for 
M. pneumoniae was not available in our center, 
therefore, we had to rely only on the positive 
serology for M. pneumoniae, and the clinical fin-
dings. However, we also relied on the negativity 
of all the other complementary tests performed 
on both patients when searching for another 
etiologic agent (S. pneumoniae´s antigen was 
negative in urine samples and in pleural fluid; 
lack of bacterial growth in serial blood cultures 
and in pleural fluid; and Mantoux test negative, 
in both cases, also viral PCR were also negative, 
including test for influenza pneumonia, herpes 
virus, and most common respiratory viruses). 
These laboratory results can only support the 
diagnosis of necrotizing pneumonia caused by 
M. pneumoniae, but the clinical presentation of 
both patients, also supports this hypothesis. Ne-
ither of patients had high fever, toxic appearance, 
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respiratory distress or signs of severe systemic 
infection. Blood tests were only slightly affec-
ted with moderate increase in the inflammatory 
markers. We consider important to emphasize the 
good general condition of both patients, the rapid 
response to macrolide treatment, the lack of any 
other etiologic agent and the total recovery of both 
children in a short time. This led us to conclude, 
that the pneumonia, in both cases, might be cau-
sed by M. pneumoniae [5, 9, 10]. 
In conclusion, we would like to emphasize 
that it is rare, but not impossible, to find necro-
tizing pneumonias in children caused by this 
bacterium. Therefore, we think, it is important 
to memorize this possibility, and if clinically an 
atypical pneumonia is suspected, a macrolide 
should be added to the antibiotic regimen. Based 
on patient age, clinical and radiological factors, 
and coexisting illness empirical antibiotic treat-
ment is decided. The first line antibiotic treatment 
in patients with clinical or radiological findings 
suggestive of pneumococcal pneumonia is not 
a macrolide. Oral amoxicillin is the recommended 
initial oral drug, and other antibiotics can be used 
depending of the suspected germ. Generally, in 
severe cases an intravenous third generation ce-
phalosporin should be used, but in children aged 
4 and older, affected by a community acquired 
pneumonia, a macrolide should be added if evolu-
tion is not clinically adequate or if a Mycoplasma 
infection is clinically suspected, regardless of the 
severity of the presentation [2, 7, 9]. 
Clinical and epidemiologic features can be 
used to determine the most likely pathogens 
and to initiate an empiric therapy in children. 
When usual antibiotic empiric regimen is not 
being successful, before thinking of uncommon 
germs, we must remember that: The unusual 
presentation of a common disease is generally 
more likely than the usual presentation of an 
uncommon disease [11, 12]. 
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